GlobeStar Therapeutics Corporation
GSTC · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -48,837.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $1 | $9 | $0 |
| SG&A Expenses | $2 | $1 | $9 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $1 | $9 | $0 |
| Operating Income | -$2 | -$1 | -$9 | -$0 |
| % Margin | – | – | – | -394,805.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | -$0 |
| Pre-Tax Income | -$2 | -$1 | -$10 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$1 | -$10 | -$1 |
| % Margin | – | – | – | -703,896.1% |
| EPS | -0.002 | -0.002 | -0.02 | -0.002 |
| % Growth | 0% | 88.2% | -1,027.8% | – |
| EPS Diluted | -0.002 | -0.002 | -0.02 | -0.002 |
| Weighted Avg Shares Out | 827 | 629 | 482 | 298 |
| Weighted Avg Shares Out Dil | 827 | 629 | 482 | 298 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $0 | $0 | $0 |
| EBITDA | $0 | -$1 | -$9 | -$0 |
| % Margin | – | – | – | -392,207.8% |